State Street Corp Grows Holdings in Iovance Biotherapeutics, Inc ...

Dec 15, 2024 · State Street Corp raised its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 4.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission.The firm owned …

6%
OFF

State Street Corp Grows Holdings In Iovance Biotherapeutics, Inc ...

2 weeks from now

marketbeat.com

7%
OFF

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Bought By …

2 weeks from now

Dec 18, 2024 · A number of other institutional investors also recently bought and sold shares of the company. Quest Partners LLC grew its stake in Iovance Biotherapeutics by 1,237.7% …

defenseworld.net

$7.22
OFF

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Acquired By ...

2 weeks from now

Dec 20, 2024 · Iovance Biotherapeutics Trading Down 0.6 %. Shares of Iovance Biotherapeutics stock opened at $7.22 on Friday. Iovance Biotherapeutics, Inc. has a 52 week low of $6.70 …

etfdailynews.com

$503000.00
OFF

Iovance Biotherapeutics (IOVA) Gets A Buy From Truist Financial

2 weeks from now

1 day ago · Most recently, in November 2024, Ryan Maynard, a Director at IOVA sold 50,000.00 shares for a total of $503,000.00. ... Iovance Biotherapeutics, Inc. operates as a biotechnology …

businessinsider.com

$22.00
OFF

Goldman Sachs Reiterates Buy On Iovance Stock Following Meeting …

2 weeks from now

1 day ago · On Tuesday, Goldman Sachs reaffirmed their Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) with a steadfast $22.00 price target. The endorsement follows a recent …

investing.com

0%
OFF

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 7.8

2 weeks from now

5 days ago · Daiwa Securities Group Inc. lifted its position in shares of Iovance Biotherapeutics by 754.0% during the second quarter. Daiwa Securities Group Inc. now owns 8,813 shares of the …

marketbeat.com

$5.91
OFF

Oversold Conditions For Iovance Biotherapeutics (IOVA)

2 weeks from now

1 day ago · In trading on Monday, shares of Iovance Biotherapeutics Inc (Symbol: IOVA) entered into oversold territory, hitting an RSI reading of 26.3, after changing hands as low as $5.91 per …

nasdaq.com

8%
OFF

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Purchased By ...

2 weeks from now

Dec 21, 2024 · Barclays PLC increased its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 118.8% in the third quarter, according to its most recent 13F filing with the …

marketbeat.com

$22.00
OFF

Analysts Offer Insights On Healthcare Companies: Iovance ...

2 weeks from now

2 days ago · Barclays analyst Peter Lawson maintained a Buy rating on Iovance Biotherapeutics on January 10 and set a price target of $22.00. The company’s shares closed last Friday at …

businessinsider.com

$5.77
OFF

Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 1-Year Low …

2 weeks from now

1 day ago · Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) shares hit a new 52-week low during trading on Tuesday . The stock traded as low as $5.77 and last traded at …

marketbeat.com

$444.04
OFF

Iovance Biotherapeutics (IOVA) Earnings Date And Reports 2025

2 weeks from now

5 days ago · Most Bought Stocks; Members of Congress; Corporate Events. Corporate Buybacks; ... Iovance Biotherapeutics (NASDAQ:IOVA) has a recorded net income of -$444.04 million. …

marketbeat.com

25%
OFF

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) May Have Run Too …

2 weeks from now

4 days ago · To the annoyance of some shareholders, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shares are down a considerable 25% in the last month, which continues a …

simplywall.st

$23.00
OFF

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $23.00 …

2 weeks from now

Jan 5, 2025 · NASDAQ IOVA opened at $7.65 on Thursday. The firm has a market cap of $2.33 billion, a price-to-earnings ratio of -5.13 and a beta of 0.57. The company has a 50-day simple …

etfdailynews.com

$26500000
OFF

Iovance Biotherapeutics Insider Bought Shares Worth $26,500,000 ...

2 weeks from now

Sep 18, 2023 · Wayne P. Rothbaum, Director, on September 15, 2023, executed a purchase for 5,000,000 shares in Iovance Biotherapeutics NASDAQ:IOVA for $26,500,000. Following the …

tradingview.com

11%
OFF

Iovance Biotherapeutics (IOVA) Market Capitalization Overview

2 weeks from now

2 days ago · As of Jan 13, 2025, Iovance Biotherapeutics (IOVA) has a market capitalization of $1.77B.Over the past 30 days, its market cap has decreased by -14.11%, while in the last 12 …

public.com

6%
OFF

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Sold By …

2 weeks from now

Dec 12, 2024 · Walleye Capital LLC reduced its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 45.6% in the 3rd quarter, HoldingsChannel reports. The …

tickerreport.com

$12.93
OFF

Marshall Wace LLP Invests $12.93 Million In Iovance …

2 weeks from now

Sep 29, 2024 · Marshall Wace LLP acquired a new stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) in the second quarter, according to its most recent 13F filing …

marketbeat.com

FAQs about State Street Corp Grows Holdings in Iovance Biotherapeutics, Inc ... Coupon?

Should you buy iovance Biotherapeutics (Iova) stock?

Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) have received a consensus rating of “Moderate Buy” from the eight research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. ...

How much did iovance Biotherapeutics earn in a quarter?

Iovance Biotherapeutics last announced its earnings data on May 9th, 2024. The biotechnology company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.03. The business earned $0.72 million during the quarter, compared to the consensus estimate of $1.99 million. ...

Does Principal Financial Group own iovance Biotherapeutics?

Principal Financial Group Inc. lifted its holdings in shares of Iovance Biotherapeutics by 59.0% in the third quarter. Principal Financial Group Inc. now owns 4,033,184 shares of the biotechnology company’s stock worth $37,872,000 after buying an additional 1,496,941 shares in the last quarter. ...

Where is iovance Biotherapeutics headquartered?

The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report) today. ...

How do I receive news & ratings for iovance Biotherapeutics?

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter. ...

When is iovance Biotherapeutics' next earnings release date?

Iovance Biotherapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 13th, 2024 based off last year's report dates. Learn more on IOVA's earnings history. Did Iovance Biotherapeutics beat their earnings estimates last quarter? ...